•Meta analysis using the most serious outcome reported shows 66% [52‑76%] and 86% [75‑92%] improvement for early treatment and prophylaxis, with similar results after exclusion based sensitivity analysis (which excludes all of the GMK/BBC team studies), with primary outcomes, and after restriction to peer-reviewed studies or Randomized Controlled Trials.
•Statistically significant improvements are seen for mortality, ventilation, ICU admission, hospitalization, recovery, cases, and viral clearance. 30 studies show statistically significant improvements in isolation.
•Results are very robust — in worst case exclusion sensitivity analysis 52 of 63 studies must be excluded to avoid finding statistically significant efficacy.
Bottom line: Ivermectin works to reduce the effects of Covid.